Psoriasis: Review of the management and treatment with first line topical therapies

August 6, 2022

Topical medications are those applied directly to the skin, such as creams, lotions, and ointments.

What is Psoriasis?


Psoriasis is an autoimmune skin disease characterized by rapidly growing skin cells and the appearance of plaques with red and scaly lesions on the skin. It is estimated that this chronic condition affects 3.2% of the US population and not only affects the appearance of the skin, it can also predispose to the development of other diseases.


If you have mild-to-moderate psoriasis, your doctor will most likely start you on some of the following topical treatments: steroids, calcineurin inhibitors, vitamin D analogs, or retinoids.


What is a topical treatment? Topical medications are those applied directly to the skin, such as creams, lotions, and ointments. These are considered first-line therapy to treat mild-to-moderate psoriasis. One of the advantages of using topical drug therapy is that they have fewer side effects than other alternatives, such as oral and injectable medications. Your doctor will choose the most suitable treatment based on the severity and location of the lesions, as well as other factors such as age, pregnancy status and others. In this article you will find information about the first-line therapy options available to treat psoriasis.


What can I do for my Psoriasis?


Since psoriasis is unique for each individual, and drugs work differently on different patients, it can be a challenge to manage. Finding the most effective therapy can be a process of trial and error, and can often be frustrating. Therefore, the most important thing you can do is stay informed about what alternatives are available and consult with your doctor or pharmacist regularly. 


References:

Elmets, C. A., Korman, N. J., Prater, E. F., Wong, E. B., Rupani, R. N., Kivelevitch, D., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., Elewski, B. E., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Kaplan, D. H., Kavanaugh, A., Kiselica, M., Kroshinsky, D., Lebwohl, M., … Menter, A. (2021). Joint AAD–NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal of the American Academy of Dermatology, 84(2), 432–470. https://doi.org/10.1016/j.jaad.2020.07.087

Mayo Foundation for Medical Education and Research. (2022, June 4). Psoriasis. Mayo Clinic. Retrieved July 13, 2022, from https://www.mayoclinic.org/diseases-conditions/psoriasis/diagnosis-treatment/drc-20355845

WebMD. (n.d.). Topical creams & lotions to treat psoriasis. WebMD. Retrieved July 13, 2022, from https://www.webmd.com/skin-problems-and-treatments/psoriasis/topical-treatments-psoriasis 


First-Line Options for Mild-Moderate Psoriasis:




Treatment Uses How it works? Adverse effects Comments
Corticosteroids betamethasone dipropionate (Diprolene), fluocinonide (Lidex), desonide (DesOwen), hydrocortisone and others Used for short periods of time to treat active lesions Reduces redness, swelling, and irritation of the skin Skin thinning, changes in pigmentation, easy bruising, stretch marks, and redness Once the lesions are controlled, your doctor will gradually reduce the use of the corticosteroid until it is discontinued. Abrupt discontinuation can result in exacerbation of the symptoms.
Calcineurin Inhibitors: tacrolimus (Protropic) and pimecrolimus (Elidel) Used in more sensitive areas such as the facial area and genitals where steroids can cause irritation Calm the rash and reduce scaly buildup Burning sensation and pruritus Should be used with caution in pregnant women. Talk to your doctor if you are pregnant or planning to become pregnant.
Vitamin D Analogs: calcipotriene (Dovonex, Sorilux) and calcitriol (Vectical) Used in conjunction with topical steroids has proven to be effective, so your doctor may choose to combine both alternatives to manage your condition Slow rapidly growing skin cells, flatten thick psoriasis, and remove scales Irritated skin, burning, itching, swelling, peeling, dryness, and redness Vitamin D analogues may be used during pregnancy and lactation if the benefit outweighs the risk.
Retinoids: tazarotene (Tazorac) The use of topical tazarotene for 8 to 12 weeks is recommended for the treatment of mild-to-moderate psoriasis Reduces the redness, number, and size of skin lesions Peeling, redness, burning sensation, irritation, and pain Tazarotene should not be used in women who are pregnant or planning to become pregnant. A negative pregnancy test must be obtained two weeks before starting treatment. Discuss with your doctor if there is a possibility or if you are planning to become pregnant to determine an alternative treatment
A stethoscope is laying on a piece of paper next to a pen
December 12, 2024
URAC accreditation reflects ProCare Rx’s commitment to achieving and maintaining the highest quality, member engagement and experience, and operational standards for PBMs in the industry
By Mc-Rx Team November 15, 2024
Mental health parity and medication adherence
By MC-Rx Clinical Team August 7, 2024
Understanding GLP-1 Medications The landscape of obesity management is evolving, with GLP-1 receptor agonist (RA) medications emerging as a significant player. These FDA-approved drugs have proven effective in helping individuals lose weight, prompting a shift in how they are viewed and covered by health plans. However, the cost implications and strategic decisions surrounding these medications require careful consideration by employer groups and their members. The Case for GLP-1 Medications GLP-1 RAs, originally developed for diabetes management, have shown remarkable efficacy in weight loss. With the growing prevalence of obesity and its associated healthcare costs, there's increasing pressure on health plans to cover these medications. Despite their high cost—annual retail pharmacy expenses can exceed $10,000 per patient—GLP-1 RAs offer potential downstream savings by reducing obesity-related comorbidities such as diabetes, hypertension, and cardiovascular disease​​. Balancing Coverage and Cost Historically, weight loss medications were deemed "lifestyle" drugs and excluded from coverage. However, the rising popularity of GLP-1 RAs and their demonstrated benefits are challenging this perspective. For plan sponsors, the decision to cover these medications involves balancing the high upfront costs with the potential for long-term savings on medical expenses related to obesity. Cost-Containment Strategies For payers choosing to cover GLP-1 medications, several cost-containment strategies can be employed: Formulary Management : Deciding on the placement of these medications within the formulary is crucial. Options range from not covering the drugs to placing them on a high-cost tier with patient cost-sharing. Prior Authorization and Step Therapy : Implementing these measures ensures that only patients with a proper diagnosis (e.g., ICD-10 code for obesity) access these medications, preventing misuse and overutilization. Prerequisite Programs : Requiring participation in wellness or nutrition programs before approving weight loss medications can encourage lifestyle modifications that complement pharmacological treatment. Specialist Restrictions : Limiting prescriptions to weight loss specialists, such as bariatric doctors or endocrinologists, ensures appropriate therapy and monitoring. Duration Limits : Establishing treatment guidelines, such as discontinuing medications if a target weight loss is not achieved within six months, helps manage long-term costs​​. The Role of Brokers and Employer Groups Brokers play a pivotal role in guiding employer groups through the complexities of covering GLP-1 medications. Understanding the cost-benefit dynamics and available cost-containment strategies enables brokers to provide informed recommendations that align with their clients' financial and health objectives. Employer groups, in turn, must weigh the potential benefits of covering these medications against their budgetary constraints and the overall well-being of their workforce. Member Education and Engagement Effective communication with members is essential to ensure they understand the coverage options and adhere to prescribed treatments. Educational initiatives can include: Patient Communication Programs : Providing information on medication adherence, compliance, and lifestyle modifications. Continuing Education : Ongoing programs to keep members informed about the benefits and proper use of weight loss medications. Monitoring and Support : Utilizing pharmacy and medical data to track outcomes and adjust strategies as needed​​. Balance the Scale with Expert Guidance from MC-Rx The adoption of GLP-1 medications for weight loss represents a significant advancement in obesity management. However, the high costs associated with these drugs necessitate careful planning and strategic implementation by brokers, employer groups, and members. By employing robust cost-containment strategies and prioritizing member education, health plans can navigate the financial challenges while delivering meaningful health benefits to their populations. MC-Rx, as a full-service pharmacy benefits manager, offers the expertise and tools to help clients optimize their coverage decisions and manage the complexities of incorporating GLP-1 medications into their health plans. Here are just a few of the GLP-1 strategies we use to shield our clients from excessive costs: Implementation of Drug Management Tools, which is critical to ensure proper utilization for GLP-1s. Strategic Benefit Design, which also protects clients from improper GLP-1 utilization. Clear Member Communication, which is crucial for proper adherence and compliance. When implemented with an existing client, the above-listed strategies helped them achieve $382,000 in cost avoidance for GLP-1s. With the right approach, the benefits of these medications can be realized, contributing to better health outcomes and potentially lowering overall healthcare costs in the long run. For more information on managing GLP-1 medications and other pharmacy benefits, reach out to an MC-Rx expert today .
By MC-Rx Clinical Team August 2, 2024
Mental Health Parity and Medication Adherence
March 21, 2024
MC-Rx, powered by ProCare Rx, has been notified by the Academy of Managed Care Pharmacy (AMCP) of the acceptance of their abstract, “Improving Adherence to HIV PREP via a PBM-Driven Educational Intervention” , for presentation at AMCP 2024 Conference in April.
February 23, 2024
Exploring the rising costs and demands of weight-loss medication and how to combat those costs, significantly lowering drug costs for payors and increasing access for patients who need them.
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 10, 2024
To decrease the burden on healthcare costs, at MC-Rx we strive to create awareness by educating our community regarding the importance of prevention.
September 28, 2023
Increased medication adherence has been linked to better clinical and financial outcomes.
More Posts
Share by: